EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Construction and Expression of Fc-FGF21 by Different Expression Systems and Comparison of Their Similarity and Difference with Efruxifermin by In Vitro and In Vivo Studies

Xujia Wang, Qin Meng, Aijuan Jia, Yuehua Zhou, Dandan Song, Shaokang Ma, Wei Li, Zhuobing Zhang, Christopher Goldring, Hui Feng, Mu Wang

Applied Biochemistry and Biotechnology · 2025

DOI: 10.1007/s12010-024-05107-x ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Applied Biochemistry and Biotechnology, 2025. Verfasst von Xujia Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, 111 Ren'ai Road, SD334F, Suzhou, 215123, Jiangsu, China. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Immunoglobulin Fc Fragments, Gene Expression. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-alcoholic steatohepatitis (NASH) is a potential serious disease, which almost has no available medicine for effective treatment today. Efruxifermin is a bivalent Fc-FGF21 candidate drug developed by Akero Therapeutics that has shown promising results in preclinical and clinical trials for NASH and may be approved in future. However, it is produced by Escherichia coli (E. coli) expressing system, which has no glycosylation modifications and is hard to purify for inclusion body. Suspension mammalian cell expression systems, human embryonic kidney 293 (HEK293), and Chinese hamster ovary (CHO) are good choice for protein expression of biopharmaceutical use. In this report, the objective was to produce Fc-FGF21 by mammalian cell expression systems, which enabled necessary glycosylation modifications to occur on the Fc-FGF21 protein and was relatively easy for future large-scale production. We observed that the target protein Fc-FGF21 could be easily degraded in CHO system, such as CHOK1SV or CHOZN, and it was hard to purify, whereas it was more stable in the HEK293 expressing system. Then, similarity between Fc-FGF21 from E. coli and Fc-FGF21 from HEK293 was focused by in vitro and in vivo studies, and we observed no significant difference between the proteins expressed from the two different expressing systems, indicating that a biosimilar of Efruxifermin has been developed successfully. Proteomics analysis from in vivo study samples further identified some potential biomarkers or FGF21 related signaling pathways. Taken together, this study demonstrates a good example of how to develop and validate a biosimilar for therapeutic purposes. In future, more efforts, such as mutation to FGF21 or linking FGF21 with effective antibody to form dual targets, could be done to obtain more effective FGF21 analogs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibroblast Growth FactorsImmunoglobulin Fc FragmentsGene ExpressionHumansCHO CellsCricetulusAnimalsHEK293 CellsEscherichia coliMiceGlycosylation

Stichwörter der Autor:innen

BiosimilarEfruxiferminExpression systemFc-FGF21Similarity

Substanzen

Fibroblast Growth Factorsfibroblast growth factor 21Immunoglobulin Fc FragmentsFGF21 protein, human

Autor:innen und Institutionen

  • Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, 111 Ren'ai Road, SD334F, Suzhou, 215123, Jiangsu, China.
  • Department of Analytical Science, Shanghai Junshi Biosciences Co., Ltd, Shanghai, China.
  • Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, UK.
  • Shanghai Anlingke Biopharmaceutical Co., Ltd, Shanghai, China.
  • Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, 111 Ren'ai Road, SD334F, Suzhou, 215123, Jiangsu, China. mu.wang@xjtlu.edu.cn.

Zitieren

APA

Wang, X., Meng, Q., Jia, A., Zhou, Y., Song, D., Ma, S., Li, W., Zhang, Z., Goldring, C., Feng, H., & Wang, M. (2025). Construction and Expression of Fc-FGF21 by Different Expression Systems and Comparison of Their Similarity and Difference with Efruxifermin by In Vitro and In Vivo Studies. Applied Biochemistry and Biotechnology. https://doi.org/10.1007/s12010-024-05107-x

Vancouver

Wang X, Meng Q, Jia A, Zhou Y, Song D, Ma S, et al. Construction and Expression of Fc-FGF21 by Different Expression Systems and Comparison of Their Similarity and Difference with Efruxifermin by In Vitro and In Vivo Studies. Applied Biochemistry and Biotechnology. 2025. doi:10.1007/s12010-024-05107-x

BibTeX
@article{Wang2025,
  author = {Wang, Xujia and Meng, Qin and Jia, Aijuan and Zhou, Yuehua and Song, Dandan and Ma, Shaokang and Li, Wei and Zhang, Zhuobing and Goldring, Christopher and Feng, Hui and Wang, Mu},
  title = {Construction and Expression of Fc-FGF21 by Different Expression Systems and Comparison of Their Similarity and Difference with Efruxifermin by In Vitro and In Vivo Studies},
  journal = {Applied Biochemistry and Biotechnology},
  year = {2025},
  doi = {10.1007/s12010-024-05107-x}
}
Kostenlos starten →